Global Non-Small Cell Lung Cancer Drugs Market Size By Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), By Treatment (Surgery, Chemotherapy, and Radiation), By Geographic Scope And Forecast

Non-Small Cell Lung Cancer Drugs Market Size And Forecast

Non-Small Cell Lung Cancer Drugs Market size was valued at USD 21,966.68 Million in 2021 and is projected to reach USD 51,242.34 Million by 2030, growing at a CAGR of 9.4% from 2022 to 2030.

An increasing number of non-small cell lung cancer diagnoses, as well as increased awareness in developed and developing markets, are all contributing to the growth of the Non-Small Cell Lung Cancer Drugs Market. This, combined with increased investments by major players in R&D activities and the inclusion of non-small cell cancer therapeutics in the pipelines of major market players, is boosting the global market growth. The Global Non-Small Cell Lung Cancer Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Non-Small Cell Lung Cancer Drugs Market Definition

Non-small-cell lung cancer is defined as any type of epithelial lung cancer that is not small-cell lung cancer. NSCLC accounts for approximately 85% of all lung cancers. When compared to small-cell carcinoma, NSCLCs are relatively insensitive to chemotherapy. When possible, they are treated primarily through surgical resection with curative intent, though chemotherapy is increasingly being used both preoperatively and postoperatively.

The most common types of NSCLC are squamous cell carcinoma, large-cell carcinoma, and adenocarcinoma, but several other types occur less frequently. Pleomorphic, carcinoid tumors, salivary gland carcinoma, and unclassified carcinoma are a few of the less common types. All types can exist in unusual histologic variants as well as mixed cell-type combinations. Non-squamous-cell carcinoma accounts for nearly half of all NSCLC. The central type accounts for roughly one-ninth of the tissue classification. When a more specific diagnosis cannot be made, the phrase “not otherwise specified” (NOS) is used generically. When a pathologist examines a small number of malignant cells or tissue in a cytology or biopsy specimen, this is most often the case.

Lung cancer in people who have never smoked is almost always NSCLC, with adenocarcinoma accounting for a sizable proportion. Malignant lung tumors have been found to contain components of both SCLC and NSCLC on rare occasions. The tumors in these cases are classified as combined small-cell lung carcinoma (c-SCLC) and treated as “pure” SCLC. Many of the symptoms of NSCLC can be mistaken for those of other diseases, but having chronic or overlapping symptoms may be a sign of the disease’s presence. Some symptoms indicate a less advanced case, while others may indicate that cancer has spread. Chronic cough, coughing up blood, hoarseness, shortness of breath, wheezing, chest pain, weight loss, and loss of appetite are some of the symptoms of less advanced cancer.

Feeling weak, being very tired, having difficulty swallowing, swelling in the face or neck, and continuous or recurring infections such as bronchitis or pneumonia are some other symptoms associated with the early progression of the disease. Bone pain, nervous-system changes (headache, weakness, dizziness, balance problems, seizures), jaundice, lumps near the body’s surface, numbness of extremities due to Pancoast syndrome, and nausea, vomiting, and constipation caused by hypercalcemia are all symptoms of a more advanced case. Shortness of breath, superior vena cava syndrome, difficulty swallowing, large amounts of mucus, weakness, fatigue, and hoarseness are some other symptoms that indicate cancer progression.

Global Non-Small Cell Lung Cancer Drugs Market Overview

The growth drivers for the market are the Increasing Prevalence of Lung Cancer, Rising Pollution due to Rapid Industrialization and the Rise in the Number of Smokers, and Increasing Funding in the Field of Research and Development of New Drugs. Increased adoption and demand for targeted therapies, which are considered to be the foundation of precision medicine due to increased R&D initiatives and also due to their sophistication in targeting cancerous cells, is one of the most prominent driving factors responsible for the growth of the Global NSCLC Market. Among therapy types, targeted therapy is expected to have the largest market share. The targeted therapy segment held the largest market share, which is expected to grow during the forecast period.

The increasing emphasis on lung cancer diagnosis and subsequent treatment based on accurate targeting of the tumor or the source of the cancer is also driving the targeted therapy segment. During the forecast period, the immunotherapy segment is expected to grow at a faster rate. This is due to an increase in the number of product launches, particularly in the immunotherapy segment. Currently, there is increasing adoption of immunotherapy in developing-country markets due to improved patient outcomes as a result of efficient treatment, which is expected to contribute to market growth at a good CAGR during the forecast period. The restraints for the market growth are the Side Effects of Drugs and the High Cost of Therapies. Whereas the opportunities are the development of drugs and treatment in Emerging economies.

Global Non-Small Cell Lung Cancer Drugs Market Segmentation Analysis

The Global Non-Small Cell Lung Cancer Drugs is segmented on the basis of Type, Treatment, And Geography.

Non-Small Cell Lung Cancer Drugs Market, By Type

• Adenocarcinoma• Squamous cell carcinoma• Large cell carcinoma• Large cell neuroendocrine tumors

Based on Type, The market is bifurcated into Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma, and Large cell neuroendocrine tumors. Squamous cell carcinoma (SCC) is found in the squamous cells near the bronchus in the middle of the lungs. Large cell carcinoma, also known as undifferentiated carcinoma, can occur in any part of the lung, grows quickly, and is difficult to treat. Adenocarcinoma has a slower growth rate than the other two types and is found in cells responsible for mucous secretion in the outer lung parts.

Non-Small Cell Lung Cancer Drugs Market, By Treatment

• Surgery• Chemotherapy• Radiation

Based on Treatment, The market is bifurcated into Surgery, Chemotherapy, and Radiation. The first two stages of NSCLC are treated with surgery, which includes pneumonectomy (removal of the entire lung), lobectomy (removal of a section of the lung), and wedge resection (exclusion of part of the lobe). Chemotherapy is prescribed for a significant number of lung cancer patients. Other chemotherapeutic drugs used include carboplatin and cisplatin. When surgical procedures are not an option, the third type of treatment, radiation, is used in stages one and two of NSCLC. Beta-blockers are annotated in radiation therapy for disease-free patient survival. NSCLC is diagnosed through a two-stage process of testing and staging. Radiography, X-ray, bronchoscopy, or CT biopsy are used to aid in testing.

Non-Small Cell Lung Cancer Drugs Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

Based on Geography, The market is bifurcated into North America, Europe, Asia Pacific, and the Rest of the world. In the estimated period, North America is expected to have the largest market share, followed by Europe. Growing smoking habits in developing countries in the Asia Pacific region are also expected to contribute significantly to the Non-Small Cell Lung Cancer Drugs Market.

Key Players

The “Global Non-Small Cell Lung Cancer Drugs Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Agennix AG, ArQule Inc., GlaxoSmithKline Pharmaceuticals Limited, Daiichi Sankyo Co. Ltd., Sanofi-Aventis, and Boehringer Ingelheim GmbH, Pfizer. The competitive landscape section also includes the above-mentioned players’ key development strategies, market share, and market ranking analysis.

Key Developments

• In March 2021, Pfizer Inc. has received FDA approval to broaden the indication for LORBRENA (lorlatinib) to include first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is now approved for adults with metastatic NSCLC whose tumors tested positive for ALK using an FDA-approved test.

• In May 2021, The European Commission has approved Roche’s Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.